ALAMEDA, Calif. — October 3, 2025 — Leads & Copy — Vivani Medical, Inc. (NASDAQ: VANI) has announced a temporary withdrawal of the previously announced record date for the planned spin-off of its wholly-owned subsidiary, Cortigent, Inc., due to delays stemming from the current U.S. federal government shutdown.
The company expects to reestablish and announce a new record date as soon as possible. Cortigent is developing brain implant devices with neuromodulation technology. ThinkEquity is the exclusive financial advisor for the spin-off.
Cortigent is working on brain implant devices to help patients recover critical body functions, leveraging neuroscience, microelectronics, and AI to create neurostimulation brain-computer interfaces (BCIs). Its predecessor, Second Sight Medical Products, marketed Argus® II, a device for treating a rare form of blindness. Cortigent’s next-generation system, Orion® Visual Cortical Prosthesis System, is designed to treat blindness caused by glaucoma and diabetic retinopathy. Cortigent is also applying its neurostimulation technology to improve recovery of arm and hand motion in patients with paralysis due to stroke.
Vivani Medical, Inc. develops biopharmaceutical implants using its NanoPortal™ platform to deliver drug molecules steadily over time. They are developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. The implants aim to avoid challenges associated with daily or weekly medication administration.
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com
(415) 506-8462
Media Contact:
Sean Leous
ICR Healthcare
Sean.Leous@ICRHealthcare.com
(646) 866-4012
Source: Vivani Medical, Inc.
